Aspire Biopharma Holdings(ASBP)
$8.30+0.24 (+2.98%)
ASBP
Aspire Biopharma Holdings financials statements
$8.30
At close:+0.24 (+2.98%)
Aspire Biopharma Holdings (ASBP) Ratios
194 Followers
Aspire Biopharma Holdings Ratios
ASBP's free cash flow for Q2 2026 was $-2.12M. For the 2026 fiscal year, ASBP's free cash flow was increased by $0.00 and operating cash flow was $-2.12M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.17 | 0.09 | 0.20 | 3.62 | 1.00 |
| Quick Ratio | 0.14 | 0.09 | 0.20 | 3.62 | 1.00 |
| Cash Ratio | 0.13 | 0.00 | 0.00 | 1.64 | 0.00 |
| Solvency Ratio | -2.14 | -7.43 | 14.39 | 0.30 | 0.01 |
| Operating Cash Flow Ratio | -0.65 | -0.16 | -1.62 | -4.64 | -0.00 |
| Short-Term Operating Cash Flow Coverage | -3.56 | -0.21 | -52.74 | -50.37 | -0.00 |
| Net Current Asset Value | $ -6.38M | $ -1.54M | $ -322.11K | $ -10.02M | $ -475.00 |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 1.06 | 8.56 | 0.00 | 0.00 | 0.81 |
| Debt-to-Equity Ratio | -0.22 | -0.82 | 0.00 | 0.00 | -502.31 |
| Debt-to-Capital Ratio | -0.28 | -4.64 | 0.00 | 0.00 | 1.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | -0.21 | -0.10 | 1.02 | 1.04 | -617.31 |
| Debt Service Coverage Ratio | -1.14 | -31.07 | 271.85 | 119.41 | -0.11 |
| Interest Coverage Ratio | -2.27 | 3.46 | -149.45 | 0.00 | 0.00 |
| Debt to Market Cap | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 6.63 | 0.54 | 0.00 | 0.00 | 0.01 |
| Net Debt to EBITDA | -0.03 | -0.11 | 0.00 | -0.14 | -9.36 |
| Profitability Margins | |||||
| Gross Profit Margin | -1.87% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | -312016.95% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | -182712.72% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | -312016.95% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | -394725.06% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | -394725.06% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | -394725.06% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 126.51% | 405.90% | -333.13% | -342.09% | 99.98% |
| Return on Assets (ROA) | -1865.68% | -8471.58% | 22.34% | 1.11% | -8.69% |
| Return on Equity (ROE) | 383.93% | 814.04% | 22.80% | 1.16% | 5363.16% |
| Return on Capital Employed (ROCE) | 308.11% | 200.55% | -6.84% | -0.33% | 5364.21% |
| Return on Invested Capital (ROIC) | 395.26% | -48.30% | -6.84% | -0.33% | -4.80% |
| Return on Tangible Assets | -1865.68% | -8471.58% | 22.34% | 1.11% | -8.69% |
| Earnings Yield | -10.34% | -0.13% | 0.01% | 0.01% | -0.00% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | -0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -43976.61 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 14625.42 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 58602.03 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 14625.42 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -3.29 | -0.38 | -0.01 | -0.01 | -0.00 |
| Free Cash Flow Per Share | -3.29 | -0.38 | -0.01 | -0.01 | -0.00 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | -217702.33 | -352196.50 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | -217702.33 | -352196.50 | 0.00 |
| Operating Cash Flow Coverage Ratio | -3.56 | -0.21 | -52.74 | -50.37 | -0.00 |
| Operating Cash Flow to Sales Ratio | -793.85 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -2.08% | -0.00% | -0.00% | -0.00% | -0.00% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -9.67 | -759.49 | 7486.00 | 15633.30 | -392149.17 |
| Price-to-Sales (P/S) Ratio | 38181.40 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | -37.14 | -6181.98 | 1706.80 | 180.63 | -21031578.95 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -48.10 | -35902.35 | -51166.94 | -37063.99 | -38423076.92 |
| Price-to-Operating Cash Flow Ratio | -48.10 | -35902.35 | -51166.94 | -37063.99 | -38423076.92 |
| Price-to-Earnings Growth (PEG) Ratio | 0.19 | 2.57 | 68.62 | -5.62 | 0.00 |
| Enterprise Value Multiple | -20.93 | -817.64 | 5757.67 | 15632.05 | -392081.58 |
| Enterprise Value | 237.18M | 9.52B | 33.42B | 52.21B | 9.99B |
| EV to EBITDA | -20.93 | -817.64 | 5757.67 | 15632.05 | -392081.58 |
| EV to Sales | 38242.81 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -48.17 | -35907.11 | -51166.96 | -37063.66 | -38423994.60 |
| EV to Operating Cash Flow | -48.17 | -35907.11 | -51166.96 | -37063.66 | -38423994.60 |
| Tangible Book Value Per Share | -4.27 | -2.23 | 0.26 | 2.28 | -0.00 |
| Shareholders’ Equity Per Share | -4.27 | -2.23 | 0.26 | 2.28 | -0.00 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | -0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -16.38 | -18.17 | 0.06 | 0.03 | -0.00 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.27 | 1.08 | 1.00 | 1.00 | 0.00 |
| Research & Development to Revenue | 148.97 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 2971.18 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 2278.50 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.20 | 0.20 | -0.15 | -0.42 | 9.36 |
Currency in USD

